HD肝病治疗仪在肝硬化患者中的应用效果观察  

Clinical effect of the HD medical instrument for hepatic fibrosis and cirrhosis

作　　者：王小东 付晓琳 路立业 赵蕊 

机构地区：[1]解放军第二O二医院传染科,辽宁沈阳110812

出　　处：《海南医学》2012年第9期31-33,共3页Hainan Medical Journal

摘　　要：目的观察HD肝病治疗仪在肝硬化治疗过程中的临床效果,探讨其稳定肝功能、抵抗纤维化的机制。方法选择2009年2月至2011年2月在我科治疗的肝硬化57例,随机分为对照组28例和观察组29例,对照组行常规保肝治疗,观察组在此基础上加用HD肝病治疗仪治疗,比较两组患者治疗前后临床症状、肝功能及纤维化指标的变化。结果观察组患者在肝区隐痛、腹胀、食欲减退改善明显优于对照组(P<0.05),差异具有统计学意义;经血清学检查反应肝功能的指标,两组患者ALT差异不明显(P>0.05),无统计学意义;观察组患者纤维化指标AST、GGT、ALP比对照组改善更为明显(P<0.05),差异具有统计学意义;观察组患者肝纤维化指标均明显优于对照组(P<0.05),差异具有统计学意义。结论 HD肝病治疗仪能明显改善患者的临床症状,恢复肝功能,降低肝纤维化指标,值得临床推广使用。Objective To observe the effect of HD medical instrument in the treatment of hepatic fibrosis and cirrhosis,and explore the its stability to liver function,and the mechanism of fibrosis resistance.Methods From February 2009 to February 2011,57 cases with hepatic fibrosis and cirrhosis were randomly divided them into control group （28 cases） and observation group （29 cases）.The control group were treated with routine treatment.;the observation group were treated with HD medical instrument based on routine treatment.And clinical symptoms,liver function and fibrosis index change were compared in two groups.Results The clinical symptoms in observation group,such as chest pain,bloating,anorexia improved better than those in the control group （P 0.05）;serologic examination of liver function indexes about ALT showed no significant difference between two groups;AST,GGT,ALP in observation group improved obviously than those in the control group （P 0.05）;the liver fibrosis indexes such as HA,LN,PCIII,IV-C in the observation group were significantly improved than those in the control group （ 0.05）.Conclusion HD medical instrument can obviously improve clinical symptoms and liver function,converse liver fibrosis,and is worthy of clinical use.

关 键 词：肝病治疗仪 肝纤维化 肝硬化 

分 类 号：R575[医药卫生—消化系统]